[ad_1]
NEW YORK, Aug. 3, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, PC reminds investors that clbad action lawsuits have been filed on behalf of the shareholders of Sunlands Technology Group, Fred & s, Inc., and Acer Therapeutics, Inc. and Diebold Nixdorf, Inc.. Additional information on each case is available on the link provided.
Sunlands Technology Group (NYSE: STG)
Principal Applicant Deadline: August 26, 2019
Clbad Period: from 20/03/2018 to 27/06/2019 ("Clbad Period") and / or under the Sunlands IPO on 3/23/2018 .
The complaint, filed on June 27, 2019, alleges that throughout the recourse period, the defendants made false and / or misleading statements and / or failed to disclose that: (1) the number of students Sunlands was down; (2) Sunlands gross billing was down; (3) Sunlands marketing tactics were not as robust as those described in the registration statement; and (4) therefore, the defendants 'statements regarding Sunlands' activities, operations and prospects were materially false and misleading and / or were without reasonable foundation at all material times. When the real details entered the market, the lawsuit claims that the investors have suffered damages.
To learn more about the Sunlands clbad action, go to: https://bespc.com/stg-2
Fred's, Inc. (NASDAQ: FRED)
Principal Applicant Deadline: August 26, 2019
Period of the course: from 20 December 2016 to 28 June 2017
The complaint, filed on June 27, 2019, alleges that Walgreens Boots Alliance, Inc. ("Walgreens"), the Company and certain of their respective officers made false and misleading statements and / or failed to disclose, inter alia, the the regulatory risk of initial and revised mergers whereby Walgreens purchases Rite Aid Corp. ("Rite Aid") (the "initial merge"). Walgreens and Rite Aid had reached an agreement with Fred's for the sale of 865 Rite Aid stores for $ 950 million, as part of a fully cash transaction, to finalize the deal. initial merger (the "Fred's Asset Purchase Agreement").
On January 30, 2017, Rite Aid and Walgreens announced the conclusion of a new merger agreement (the "Revised Merger"). On June 29, 2017, Rite Aid and Walgreens announced that they had terminated the revised merger. Following the termination of the revised merger, Walgreens terminated Fred's badet purchase agreement.
The defendants made false and misleading statements about the level of regulatory risk to which the original merger and the revised merger were exposed, which would ultimately result in the termination of the Fred Asset Purchase Agreement. Specifically, the accused made false and misleading statements: (i) downplaying or challenging the contrary information provided by reporters reporting regulatory turmoil at the close of the original merger, as well as the revised merger; and (ii) representing that the FTC's internal knowledge gave badurance that the transaction would be completed.
On this news, Fred's share price fell by $ 2.78 per share, or by more than 22.8%, from $ 12.20 per share to $ 9.41 per share on June 29, 2017. The Company's share price continued to fall over the following months, closing at $ 6.60 per share 27, 2017.
To learn more about Fred's clbad action, go to: https://bespc.com/fred
Acer Therapeutics, Inc. (NASDAQ: ACER)
Principal Applicant Deadline: August 30, 2019
Period of the course: from 25 September 2017 to 24 June 2019
The complaint, filed on July 1, 2019, alleges that throughout the Clbad Period the defendants made falsely misleading statements about the company's business, operational policies and compliance policies. Specifically, the accused made false and / or misleading statements and / or failed to disclose that: (i) Acer did not have sufficient data to support the filing of the EDSIVO NDA with the FDA for the purposes of the treatment of VEDS; (ii) the Ong study was an inadequate and poorly controlled clinical study against FDA standards; it included a group of insufficient size to allow the addition of the EDSIVO NDA; (iii) therefore, the FDA would likely reject EDSIVO NDA; and (iv) as a result, the public statements of the Company were materially false and misleading at all material times.
To learn more about the Acer Clbad Action, go to https://bespc.com/Acer
Diebold Nixdorf, Inc. (New York Stock Exchange: DBD)
Principal Applicant Deadline: September 3, 2019
Period of the course: from February 14 to July 4, 2017
The complaint, filed on July 2, 2019, alleges that throughout the Clbad Period the defendants made largely false and misleading statements about the Company's business, operational and compliance policies. Specifically, the defendants made false and / or misleading statements and / or failed to disclose that: (i) the company was experiencing delays in deploying the systems, as well as a longer decision-making process for customers and a conversion cycle of orders into revenue; (ii) the above noted issues have had an adverse effect on the Company's business and service activities; and (iii) as a result, the public statements of the Company were materially false and misleading at all material times. 5. On July 5, 2017, Diebold announced that the Company expected a larger net loss than indicated in its prior guidance for fiscal 2017, ranging from $ 50 to $ 75 million to net loss of $ 110 to $ 125 million.
The company attributed lower expectations to a delay in system deployment, a longer customer decision-making process, and an order conversion cycle to revenue. 6. As a result of this news, Diebold's share price fell by $ 6.40 per share, or nearly 23%, to $ 21.60 per share on July 5, 2017.
To learn more about the clbad action brought before Diebold Nixdorf, go to: https://bespc.com/dbd
Bragar Eagel & Squire, P.C. is a New York-based law firm specializing in commercial and securities litigation. For more information on Bragar Eagel & Squire, P.C. please go to www.bespc.com. Public Prosecutor. Previous results do not guarantee similar results.
contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com
Source link
